CCNU and methotrexate were employed as salvage treatment in 34 small cell lung cancer patients resistant to CAV/PE alternating Induction chemotherapy. In the 33 evaluable patients we observed an objective response rate of 21.2 % and 3 % complete response; median survival was 4 months with 2 patients alive 18 months from starting salvage chemotherapy. The treatment was well tolerated. CCNU and methotrexate has shown to be a moderately active and tolerable salvage treatment for small cell lung cancer after CAV/PE alternating first-line chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
BatistG., CarneyD.N., CowanK.H.: Etoposide (VP-16) and cisplatin in previously treated small cell lung cancer: clinical trial and in vitro correlates. J. Clin. Oncol., 4: 982–986, 1986.
2.
BatistG., IhdeD.C., ZabellA., LichterA.R., VeachR.S., CohenM.H., CarneyD.N., BunnP.A.: Small cell carcinoma of lung: reinduction therapy after late relapse. Ann. Intern. Med., 98: 472–474, 1983.
3.
BunnP.A.Jr., IhdeD.C.: Small cell bronchogenic carcinoma: A review of therapeutic results. Cancer Treat. Rep., 1: 169–208, 1981.
4.
CohenM.H., BroderL.E., FossieckE.B., BullM., IhdeD.C., MinnaI.D.: Combination chemotherapy with vincristine, adriamycin and procarbazine in previously treated patients with small cell carcinoma. Cancer Treat. Rep., 61: 485–487, 1977.
5.
EvansW.K., OsobaR., FeldR., SheperdF.A., BazosM.J., DeboerJ.: Etoposide (VP-16) and cisplatin: an effective treatment for relapsed small cell lung cancer. I. Clin. Oncol., 3: 65–71, 1985.
6.
FigoliF., VeronesiA., ArdizzoniA.: Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. Cancer Invest., 6: 15, 1988.
7.
GiacconeG., FerratiP., DonadioM., TestoreF., CalciatiA.: Reinduction chemotherapy in small cell lung cancer. Eur. J. Cancer Clin. Oncol., 23: 1697–1699, 1987.
8.
IhdeD.C., BunnP.A.Jr.: Chemotherapy of small cell bronchogenic carcinoma. In: Recent advanced in clinical oncology. Whitehouse J.M.A., WilliamsC.J. (Eds.), Vol. 1, pp. 305–323, Churchill Livingstone, Edinburg1982.
9.
KaplanE.L., MeierP.: Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc, 53: 457–481, 1958.
10.
LamW.K., ChanJ., SoS.Y.: Second-line chemotherapy of small cell lung cancer (SCLC) with cisplatin (DDP) and etoposide (VP-16) (abstr.). Lung Cancer, 4(suppl.): A111, 1988.
11.
LivingstonR.B., TrauthC.J., GreentreeR.L.: Small cell carcinoma: manifestations and behaviour with treatment, results of SWOG series: In: Small Cell Lung Cancer, pp. 285–300, Grane and Stratton, Orlando, 1981.
12.
LopezJ.A., MannJ., GrapskiR.T., NassifE., VannicolaP., KrikorianJ.G., FinkelH.: Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat. Rep., 69: 369–371, 1985.
13.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.
14.
MonnetI., QuoixE., RuffieP., VoisinS., SaltielJ.C., de CremouxH.: Adriamycin/cisplatin/etoposide (APE) versus carboplatin/ifospamide/vincristine (CIV) with early cross over in case of failure for patients with extensive small cell lung cancer (SCLC): preliminary results (abstr.). Proc. Second International Conference on Small Cell Lung Cancer, Ravenna, 139, 1990.
15.
O'BryanR.M., CrowleyJ.J., KimP.N., EpsteinR.B., NeilanB., ColtmanC.A., StuckeyW.J., PazdurR.: Comparison of etoposide and cisplatin with bis-chloro-ethyl-nitrosourea, thiotepa, vincristine and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study. Cancer, 65: 856–860, 1990.
16.
PerezC.A., EinhornL., OldmanR.K., GrecoF.A., CohenH.J., SilbermanH., KraussS., HornabackN., ComasF., OmuraG., SalterM., KellerJ.W., McLarenJ., KellermeyerR., StoraasliJ., BirchR., DandyM.: Randomized trial of radiotherapy in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation. A preliminary report. J. Clin. Oncol., 2: 1200–1208, 1984.
17.
PerryM.C., EatonW.L., PropertK.J., WareJ.M., ZimmerB., ChahinianP., SkarinA., CareyR.W., KreismanH., FaulknerC., ComisR., GreenM.R.: Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung. N. Engl. J. Med., 316: 912–918, 1987.
18.
PorterL.L.III, JohnsonD.H., HainsworthJ.D., HandeK.R., GrecoF.A.: Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat. Rep., 69: 479–481, 1985.
19.
PostmusP.E., BerendsenH.H., Van ZandwijkN., SplinterT.A.W., BurghoutsT.M., BakkerW.: Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur. J. Cancer Clin. Oncol., 23: 409–411, 1987.
20.
ScherH., CasperE., GrallaR.: Intensive induction chemotherapy with cisplatin (P) and etoposide (E) with radiotherapy (RT) for small cell lung cancer (SCLC) (abstr.). Proc. IV World Congress on Lung Cancer, Toronto, 15, 1985.
21.
SculierJ.P., KlasterskyJ., LibertP., RavezP., ThiriauxJ., LecomteJ., BureauG., BroheeD., MommenP.: Cyclophosphamide, adriamycine and vincristine (CAVi): an ineffective second-line chemotherapy regimen for small cell lung cancer (SCLC) (abstr.). Proc. Am. Soc. Clin. Oncol., 6: 184, 1987.
22.
ShepherdF.A., EvansW.K., MacCormickR.: Cyclophosphamide, doxorubicin, and vincristine in etoposide and cisplatin resistant small cell lung cancer. Cancer Treat. Rep., 71: 941–944, 1987.
23.
VincentM., EvansB., SmithI.: First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother. Pharmacol., 21: 45–48, 1988.
